



ResApp Wins Global Grand Finals at the 2016 Talent Unleashed Awards

Perth, Western Australia, 19 August 2016 -- ResApp Health Limited (ASX: RAP), announced today that it was awarded 'Best Tech IPO/Venture Capital Raising' at the 2016 Talent Unleashed Awards Global Grand Finals held at a ceremony last night in Sydney. Judged by an esteemed panel of international judges including Apple co-founder, Steve Wozniak and Virgin Group founder, Sir Richard Branson, the Awards recognise disruptive entrepreneurs who utilise innovative technology solutions to truly make an impact in their field.

ResApp co-founder and Executive Director, Brian Leedman said, "It was truly an honour to be recognised by Talent Unleashed and the distinguished international judging panel as a game-changing technology company. This recognition is the cumulative effort of everyone involved in helping make ResApp one of the most successful new listings on the ASX and in particular the efforts of The University of Queensland's Associate Professor Dr Udantha Abeyratne, the technology's inventor and Dr Tony Keating who has led the Company from its listing last July."

ResApp will receive prizes including spending one-on-one time with Steve Wozniak at an exclusive reception and a bespoke tour of some of Silicon Valley's leading technology companies.

- ENDS -

Contacts

Dr Tony Keating
CEO and Managing Director
+61 430 180 659
tony@resapphealth.com.au

Mr Brian Leedman
Executive Director
Vice President, Corporate Affairs
+61 412 281 780
brian@resapphealth.com.au

About ResApp Health Limited

ResApp Health Limited (ASX: RAP) is a digital health company developing smartphone applications for the diagnosis and management of respiratory disease. The technology is based on machine learning algorithms that use sound alone to diagnose and measure the severity of respiratory conditions without the need for additional hardware. The algorithms were initially developed by The University of Queensland with funding from the Bill and Melinda Gates Foundation. ResApp has both adult and



paediatric clinical studies underway with preliminary results demonstrating accurate diagnosis of pneumonia, asthma/viral wheeze, bronchiolitis, croup and upper respiratory tract infections in children as well as chronic obstructive pulmonary disease, asthma and pneumonia in adults. Markets for ResApp's technology include telehealth use through partnerships with telehealth service providers, emergency department and regular clinic use by healthcare providers, at-home use by consumers and working with global aid and humanitarian organisations to deliver tools for the developing world.

For more information on ResApp, visit www.resapphealth.com.au